Beta-blockers for prevention of oesophageal variceal rebleeding in cirrhotic patients

  • Protocol
  • Intervention

Authors

  • Wendong Chen,

    Corresponding author
    1. Toronto Health Economics and Technology Assessment Collaborative (THETA), University of Toronto, Departments of Health Policy Management and Evaluation, and Pharmacy, Toronto, Ontario, Canada
    • Wendong Chen, Departments of Health Policy Management and Evaluation, and Pharmacy, Toronto Health Economics and Technology Assessment Collaborative (THETA), University of Toronto, Room 679, 6th floor, Leslie L. Dan Pharmacy Building , 144 College Street, Toronto, Ontario, M5S 3M2 , Canada. wdchen@uhnres.utoronto.ca.

    Search for more papers by this author
  • Sarah Louise Klingenberg,

    1. Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital, Cochrane Hepato-Biliary Group, Copenhagen, Denmark
    Search for more papers by this author
  • Dimitrinka Nikolova,

    1. Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital, Cochrane Hepato-Biliary Group, Copenhagen, Denmark
    Search for more papers by this author
  • Christian Gluud

    1. Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital, Cochrane Hepato-Biliary Group, Copenhagen, Denmark
    Search for more papers by this author

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

This systematic review will evaluate the beneficial and harmful effects of beta-blockers on preventing oesophageal variceal rebleeding in cirrhotic patients who survived a variceal bleeding.